Catalyst
Slingshot members are tracking this event:
European Commission (EC) Approves Roche's (RHHBY) Alecensa for Adult Patients with Anaplastic Lymphoma Kinase ALK-Positive Advanced Non-Small Cell Lung Cancer Who Have Taken Pfizer's (PFE) Xalkori (Crizotinib)
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 21, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
European Comission, Alecensa, Adult Patients, Anaplastic Lymphoma, Kinase Alk-positive, Advanced Non-small Cell Lung Cancer, Xalkori, Crizotinib
